Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Cetuximab in Advanced Head and Neck Squamous Cell Cancer
NCT04856631Phase 2Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Apr 2021
- Primary completion
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Objective Response Rate at 2 years and Incidence and severity of adverse events and serious adverse events at 2 years. Started Apr 2021; status: completed.
02
Drugs
toripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04856631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856631.